CRISPR Therapeutics (CRSP) Tops Q3 EPS by 58c

CRISPR Therapeutics (NASDAQ: CRSP) reported Q3 EPS of ($1.41), $0.58 better than the analyst estimate of ($1.99).

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.

You May Also Be Interested In

• Oracle reports earnings today: AI spending bet faces its toughest test yet
• Wynn Resorts plans $900M senior notes offering due 2035
• Signet Jewelers (SIG) PT Raised to $136 at UBS on Strong Growth Prospects